Legend Biotech Q1 EPS $(0.34) Beats $(0.56) Estimate, Sales $36.34M Miss $37.06M Estimate
Portfolio Pulse from Happy Mohamed
Legend Biotech reported Q1 losses of $(0.34) per share, beating the $(0.56) estimate by 39.29%, but sales of $36.34M missed the $37.06M estimate by 1.95%. This represents a decrease in both EPS and sales compared to the same period last year.
May 18, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Legend Biotech's Q1 earnings beat estimates with a 39.29% higher EPS, but sales missed estimates by 1.95%. Both EPS and sales decreased compared to last year.
The mixed results of Legend Biotech's Q1 earnings report, with a better-than-expected EPS but lower sales, are likely to have a neutral short-term impact on the stock price. The decrease in both EPS and sales compared to last year may offset any positive sentiment from the EPS beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100